Osteoarthritis affects an estimated 40% of geriatric dogs and while NSAIDs are effective in mitigating the inflammatory process, they don't help with pain. Dr. Sharon Campbell, Medical Lead for Canine Chronic Pain, has been working on that for over a decade at Zoetis Animal Health. Hope is on the way with their revolutionary product, Librela, is slated to hit the US market this fall (the specific date has yet to be determined).
Librela is a monthly subcutaneous monoclonal antibody therapy, the second of its kind available for dogs, that targets Nerve Growth Factors (NGFs) thereby inhibiting pain receptors. Already in use in Europe, Librela has demonstrated considerable success in osteoarthritic patients in extending their quality of life. Yer Big Dog is anxiously awaiting to try it out for his fuzzybutt, Indiana Jones!
To find out if your canine kid is a candidate for Librela, Zoetis has a interactive webpage for pet parents: http://www.DogOAChecklist.com
--------
#FuzzybuttsAndFriends #yerbigdog #lukerobinson #gingermorgan #SharonCampbell #canineosteoarthritis #osteoarthritis #monoclonalantibodies #Librela #Zoetis #caninecancer #puppyup
